Navigation Links
Pharmaceutical study: Less hemorrhaging after stroke, but not fewer deaths
Date:6/11/2008

An international study published in May 2008 in the New England Journal of Medicine has shown that the coagulation factor VIIa can limit the extent of a cerebral hemorrhage. However, in the long term it does not prevent death or severe impairment.

Further studies must clarify whether the new treatment with the genetically engineered substance is suitable for a special group of patients who as the study suggests could profit from therapy in spite of this. These are patients with a limited hemorrhage size (delta 60ml), with limited amounts of blood in the cerebrospinal fluid space (delta 5ml), who are not over an age 70 years and who will be treated within 2.5 hours or less.

Some 841 patients in 73 centers in 20 countries took part in the study. Member of the steering committee, study coordinator for Europe, and co-author of the published article is Professor Dr. Thorsten Steiner, Senior Physician at the Department of Neurology, University of Heidelberg Hospital (Medical Director: Professor Dr. Werner Hacke).

Cerebral hemorrhages account for 15 percent of all strokes. They are often fatal; some 80 percent of the surviving patients are severely disabled. Especially problematic is further increase of the hematoma, which occurs in one third of patients in the first four hours. Thus far there is no way of treating.

An earlier study proved reduction of outcome and mortality

Three years ago, a phase-2 study with recombinant coagulation factor VIIa with the trade name NovoSeven, which is not yet approved for clinical use, showed that the compound could lower the death rate after a hemorrhage and limit impairment. This study was also published in the "New England Journal".

The new study compares the effectiveness of factor VIIa in two dosages (20 and 80 micrograms) with a placebo. The extent of the hemorrhage visible on a CT scan was noticeably larger (26%) in the placebo group than in the patients treated with 80 micrograms (11%) and 20 micrograms (18%). But there was still no difference in the number of patients who died after a stroke or were severely disabled by it. However, patients who were treated with the higher dosage of factor VIIa suffered more frequently from thromboses and embolisms.

Fewer high-risk patients in the placebo group / New study on a certain patient group?

"A decisive reason for the negative result is the fact that there were more high-risk patients in the patient groups treated with factor VIIa than in the placebo group," stated Professor Steiner. These patients more frequently had intraventricular hemorrhages (bleeding in the spaces of the brain containing cerebral spinal fluid) and high blood pressure. "Intraventricular bleeding increases the mortality by a factor of 4 to 5 and high blood pressure increases the risk of a secondary hemorrhage," said Professor Steiner. The age of the patients and timing of treatment were also factors.

"We have also determined that after a cerebral hemorrhage reaches a certain size, clinical improvement is very unlikely, irrespective of treatment," continued Professor Steiner. It is possible that the medication is effective mainly in patients whose hemorrhages have not yet exceeded a certain size, who have no or only a limited amount of blood in the ventricle, and do not exceed a certain age. This should be examined in another study.

"We would welcome a decision of the manufacturer of this medication decide to conduct a study on this special group of patients," said Professor Steiner. To what extent high blood pressure increases the risk of secondary hemorrhaging in the acute phase of a hemorrhagic stroke is currently being examined in another study.


'/>"/>

Contact: Dr. Annette Tuffs
annette.tuffs@med.uni-heidelberg.de
49-622-156-4536
University Hospital Heidelberg
Source:Eurekalert

Related medicine news :

1. Alaven Pharmaceutical Introduces Kit for UC Patients
2. GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development
3. Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent
4. Pioneering Safe Medication Return Initiative Reviewed During Pharmaceutical Disposal Summit
5. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
6. Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
7. MAP Pharmaceuticals to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
9. The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline
10. Kiss One-Size-Fits-None Goodbye: Archi-Tech Systems Offers First SFA Solution Targeted to Pharmaceutical Sales Organizations
11. Antipodean Pharmaceuticals Announces FDA Acceptance of IND for MitoQ(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 2016 , ... Sunny Isles Beach is in the Zone B floodplain where ... utility services. The time for planning is now, before a storm is approaching. , ... place. Families should follow the recommendations of the Miami-Dade County (MDC) Office of ...
(Date:5/31/2016)... ... May 31, 2016 , ... "ProDrop 3D Abstract will spark new ... level," said Christina Austin - CEO of Pixel Film Studios. , Create an ... Abstract have the ability to generate and manipulate three-dimensional shapes with ease all within ...
(Date:5/31/2016)... ... 2016 , ... Joe DiMaggio Children’s Hospital (JDCH) ... The clinic is led by a world class team of physicians, board certified ... also a team of certified vestibular therapists. , The Concussion Clinic operates ...
(Date:5/31/2016)... ... , ... According to recent statistics, there are nearly half a million ... Each physical therapy professional and every clinic has a duty to perform at ... in a competitive industry is also essential. The solution that many physical therapy leaders ...
(Date:5/31/2016)... ... May 31, 2016 , ... RF Safe's has decades of ... accessories to avoid excessive Smartphone radiation implicated in the most recent cell phone cancer ... bioRxiv preprint server on May 26th (PDF) by the National Toxicology Program ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... und GERMANTOWN, Maryland , ... Referenzdatensatz von Horizon bestätigt nachgewiesene Genauigkeit ... s   QIAGEN N.V. (NASDAQ: ... QIA) gab heute die Ergänzung seines GeneReader ... Verifizierungsdaten bekannt, die die bewährte Genauigkeit seines ...
(Date:5/31/2016)... , Germany and ... -- QIAGEN N.V. (NASDAQ: QGEN ... extensive package consisting of a quality control set and ... System, reinforcing the proven accuracy of its next-generation sequencing ... training for laboratories. QIAGEN has incorporated the Horizon Discovery ...
(Date:5/31/2016)... Mich. , May 31, 2016 Diplomat Pharmacy, ... "Diplomat Dialogue," a video conversation slated for June 7, 2016, ... event, hosted live from noon to 1 p.m. ET, will ... who helped him along the road to wellness. ... live conversations planned between patients and health care professionals, talking ...
Breaking Medicine Technology: